Lantheus Holdings今日宣布，其研发的Bravnetsa™（Lutetium Lu 177 Dotatate）已获得美国食品药品监督管理局（FDA）的最终批准。这一里程碑式的决定，标志着Bravnetsa™成为FDA认定的唯一一款在生物等效性和治疗等效性上均与Lutathera®（Lutetium Lu 177 Dotatate）相匹配的放射性药物，专门用于胃肠胰神经内分泌肿瘤（GEP-NETs）的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.